ATH alterity therapeutics limited

Ann: Alterity Phase 2 Data to be Featured at MSA Congress, page-5

  1. 1,619 Posts.
    lightbulb Created with Sketch. 642
    A listen to this
    Q1 2025 Lantheus Earnings Conference Call
    https://investor.lantheus.com/news-events/calendar-of-events

    where they discuss their product pipeline and highlights the importance and potential market neurology diagnosis will play going forward
    Better and earlier diagnosis open the market for treatment

    Lantheus are moving into the space in a big way

    https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-collaboration-provide-novel-tau-imaging-agent
    Last edited by Cornhulio: 08/05/25
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.1¢
Change
0.000(0.00%)
Mkt cap ! $100.4M
Open High Low Value Volume
1.1¢ 1.1¢ 1.1¢ $9.444K 869.4K

Buyers (Bids)

No. Vol. Price($)
36 14901464 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 14444854 13
View Market Depth
Last trade - 11.08am 18/06/2025 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.